Bayer to license Cedilla’s selective inhibitors in precision oncology
The license agreement provides Bayer with exclusive rights to develop and commercialise Cedilla’s CyclinE1/CDK2 inhibitors that are currently…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
02 Jun 23
The license agreement provides Bayer with exclusive rights to develop and commercialise Cedilla’s CyclinE1/CDK2 inhibitors that are currently…
02 Jun 23
Available commercially by the end of June, the iCell Blood-Brain Barrier Isogenic Kit is an off-the-shelf, ready-to-use cell…
02 Jun 23
In addition to the transactions, Eikon has concluded the initial portion of a Series C equity financing, securing…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
01 Jun 23
Abrysvo is a bivalent RSV prefusion F (RSVpreF) unadjuvanted vaccine that contains two preF proteins to optimise the…
01 Jun 23
Cobitolimod, a TLR9 agonist, is currently undergoing evaluation in the global phase III programme, known as CONCLUDE, as…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
01 Jun 23
The investment will include facility and equipment improvements and the addition of 60 full-time positions in 3M manufacturing…
01 Jun 23
Researchers trained a computer model to understand the connections between thousands of genes—and pinpoint how those connections go…
31 May 23
The drug discovery partnership will make use of XtalPi’s integrated AI capabilities and robotics platform to design and…
31 May 23
The platform enables a research strategy that uses Kiyatec's capacity to correctly dissociate and characterise primary patient tissues…
30 May 23
The new data is generated from preclinical studies conducted in a laboratory at the Garvan Institute of Medical…